Danaher’s Q2 revenue rose nearly 4% year-over-year to $5.94 billion, beating estimates driven by robust bioprocessing sales. Despite ongoing headwinds from China’s volume-based procurement and tariffs, the firm offset potential impacts and maintained consistent volume levels. Life sciences and diagnostics revenue segments showed moderate growth. Danaher announced CFO Matthew McGrew’s retirement set for 2026, with Matthew Gugino named as successor.